MCID: HRY003
MIFTS: 55

Hairy Cell Leukemia

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Hairy Cell Leukemia

MalaCards integrated aliases for Hairy Cell Leukemia:

Name: Hairy Cell Leukemia 12 50 29 14 69
Hairy Cell Leukemia Variant 12 56 69
Hcl-V 12 56 14
Prolymphocytic Variant of Hairy Cell Leukemia 56
Leukemic Reticuloendotheliosis Variant 56
Leukemic Reticuloendotheliosis 50
Prolymphocytic Variant of Hcl 56
Hairy Cell Leukaemia Variant 12
Leukemia, Hairy Cell 42
Leukemia Hairy Cell 52
Hcl 50

Characteristics:

Orphanet epidemiological data:

56
hairy cell leukemia variant
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/1000000 (United States); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:285 DOID:713
ICD10 33 C91.4 C91.40
ICD9CM 35 202.4
MeSH 42 D007943
NCIt 47 C7402 C7401
Orphanet 56 ORPHA300878
UMLS via Orphanet 70 C0349633
ICD10 via Orphanet 34 C91.4

Summaries for Hairy Cell Leukemia

NIH Rare Diseases : 50 hairy cell leukemia is a rare, slow-growing cancer of the blood in which the bone marrow makes too many b cells (lymphocytes), a type of white blood cell that fights infection. the condition is named after these excess b cells which look 'hairy' under a microscope. as the number of leukemia cells increases, fewer healthy white blood cells, red blood cells and platelets are produced. the underlying cause of this condition is unknown. while there is no cure, treatment can lead to remission which can last for years.   last updated: 4/3/2012

MalaCards based summary : Hairy Cell Leukemia, also known as hairy cell leukemia variant, is related to hemolytic anemia and intrapelvic lymph node leukemic reticuloendotheliosis. An important gene associated with Hairy Cell Leukemia is CCND1 (Cyclin D1), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Doxil and Gemzar have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 A chronic lymphocytic leukemia that is characterized by over production of B cells (lymphocytes) by the bone marrow where the B cells appear hairy under a microscope.

Wikipedia : 72 Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal... more...

Related Diseases for Hairy Cell Leukemia

Diseases related to Hairy Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
id Related Disease Score Top Affiliating Genes
1 hemolytic anemia 29.9 IL2 IL2RA IL3
2 intrapelvic lymph node leukemic reticuloendotheliosis 12.2
3 refractory hairy cell leukemia 12.2
4 classic hairy cell leukemia 12.1
5 splenic manifestation of hairy cell leukemia 12.0
6 leukemia 11.1
7 gastrinoma 11.0
8 mycobacterium avium complex disease 11.0
9 male infertility 10.7 IFNA1 IFNA2
10 breast ductal adenoma 10.7 IFNA1 IFNA2
11 severe combined immune deficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative, jak3-related 10.7 ADA IL2
12 generalized anxiety disorder 10.6 ADA IL2
13 reese retinal dysplasia 10.6 IFNA2 IL2
14 graft-versus-host disease, protection against 10.5 IL2 IL2RA
15 x-linked intellectual disability, van esch type 10.4 IL2 IL3
16 lymphoma 10.4
17 solitary plasmacytoma of chest wall 10.4 CCND1 IL2
18 malignant hyperthermia 10.4 IFNA1 IL2 IL2RA
19 gallbladder small cell carcinoma 10.3 ACP5 CD22
20 pyridoxine-responsive sideroblastic anemia 10.3 IFNA1 IL2 IL2RA
21 carotid artery dissection 10.3 IFNA1 IFNA2 IL2
22 benign mammary dysplasia 10.3 IFNA1 IL2 IL3
23 childhood cerebellar astrocytic neoplasm 10.3 ADA IL2 IL2RA
24 barbiturate dependence 10.3 IL2 IL2RA
25 degenerative myopia 10.3 CD5 ITGAX
26 thrombocythemia 3 10.3 IFNA1 IFNA2 IL3
27 chronic lymphocytic leukemia 10.3
28 uterine corpus epithelioid leiomyosarcoma 10.3 ADA IL2 IL2RA
29 18p deletion syndrome 10.2 IFNA1 IL2RA IL3
30 nuchal bleb, familial 10.2 CD5 IFNA1 IFNA2
31 myelofibrosis with myeloid metaplasia, somatic 10.2 IFNA1 IFNA2 IL3
32 aids wasting syndrome 10.2 IFNA1 IFNA2
33 paramyloidosis 10.2 IL2 IL2RA
34 parametritis 10.2 IL2 IL2RA
35 raynaud disease 10.2 CCND1 CD5
36 peroxisome biogenesis disorder 7a 10.2 IFNA1 IFNA2 IL3
37 bagatelle cassidy syndrome 10.2 CD5 IL2RA
38 fallopian tube endometriosis 10.2 IL2 IL2RA IL3
39 urinary bladder small cell neuroendocrine carcinoma 10.2 ACP5 BRAF CD22
40 b-cell lymphomas 10.1
41 basilar artery insufficiency 10.1 IFNA1 IFNA2 IL3
42 adrenal gland disease 10.1 ITGAE ITGAX
43 myeloid leukemia 10.1
44 carnitine-acylcarnitine translocase deficiency 10.1 BRAF IL2 IL3
45 immunodeficiency 11a 10.1 CD5 IL2 IL2RA
46 prolymphocytic leukemia 10.1
47 vasculitis 10.1
48 splenomegaly 10.0
49 sarcoma 10.0
50 malignant epithelioid hemangioendothelioma 10.0 IFNA1 IFNA2

Graphical network of the top 20 diseases related to Hairy Cell Leukemia:



Diseases related to Hairy Cell Leukemia

Symptoms & Phenotypes for Hairy Cell Leukemia

MGI Mouse Phenotypes related to Hairy Cell Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 ADA ANXA1 BRAF CCND1 CD22 CD5
2 digestive/alimentary MP:0005381 9.63 ADA ANXA1 BRAF CCND1 IL2 IL2RA
3 immune system MP:0005387 9.32 CCND1 CD22 CD5 IL2 IL2RA ITGAE

Drugs & Therapeutics for Hairy Cell Leukemia

FDA approved drugs:

(show all 11)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Doxil 17 46 DOXORUBICIN HYDROCHLORIDE Alza June 1999
2
Gemzar 17 46 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
3
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
4
Sensipar 17 CINACALCET HYDROCHLORIDE Amgen March 2004
5
Treanda 17 46 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
6
UroXatral 17 ALFUZOSIN HYDROCHLORIDE Sanofi-aventis June 2003
7
Valchlor 17 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics August 2013
8
Zuplenz 17 ONDANSETRON Strativa Pharmaceuticals July 2010
9
Patanase 17 OLOPATADINE HYDROCHLORIDE Alcon April 2008
10
Xopenex 17 LEVALBUTEROL HYDROCHLORIDE Sepracor February 2002
11
Zyrtec 17 CETIRIZINE HYDROCHLORIDE Pfizer December 1995

Drugs for Hairy Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 316)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefepime Approved Phase 3 88040-23-7 5479537
2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
3
Ofloxacin Approved Phase 3 82419-36-1 4583
4
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
6
Cladribine Approved, Investigational Phase 3,Phase 2,Phase 1 4291-63-8 20279
7
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
8
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
9
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
10
Guaifenesin Approved, Vet_approved Phase 3,Phase 2 93-14-1 3516
11
Morphine Approved, Investigational Phase 3 57-27-2 5288826
12
Ondansetron Approved Phase 3,Phase 2 99614-02-5 4595
13
Dalteparin Approved Phase 3 9005-49-6
14
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
15
Piperacillin Approved Phase 3 66258-76-2 43672
16
Tazobactam Approved Phase 3 89786-04-9 123630
17
Vancomycin Approved Phase 3 1404-90-6 441141 14969
18
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
19
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
20
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
22
Captopril Approved Phase 3 62571-86-2 44093
23
Fluconazole Approved Phase 3 86386-73-4 3365
24
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
25
Palivizumab Approved, Investigational Phase 3 188039-54-5
26
Ribavirin Approved Phase 3 36791-04-5 37542
27
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
28
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
29
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
30
Norgestimate Approved Phase 3 35189-28-7 6540478
31
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
32 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
33 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
34 Anti-Infective Agents Phase 3,Phase 2,Phase 1
35 Cephalosporins Phase 3
36 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
37 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2
38 Renal Agents Phase 3,Phase 1,Phase 2
39 Topoisomerase Inhibitors Phase 3,Phase 1,Phase 2,Early Phase 1
40 Analgesics Phase 3
41 Anesthetics Phase 3
42 Anesthetics, Dissociative Phase 3
43 Anesthetics, General Phase 3
44 Anesthetics, Intravenous Phase 3
45 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
46 Excitatory Amino Acid Antagonists Phase 3
47 Excitatory Amino Acids Phase 3
48 Neurotransmitter Agents Phase 3,Phase 2
49 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
50 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 217)

id Name Status NCT ID Phase Drugs
1 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia Completed NCT00003746 Phase 3 2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly
4 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
5 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
6 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
7 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
8 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
9 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
10 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
11 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
12 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
13 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
14 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
15 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
17 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
18 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
19 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
20 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
21 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
22 Therapy Optimisation for the Treatment of Hairy Cell Leukemia Recruiting NCT02131753 Phase 2, Phase 3 Cladribine s.c. injection, HCL treatment
23 Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia Active, not recruiting NCT01829711 Phase 3 moxetumomab pasudotox;IV Bag Protectant for Moxetumomab pasudotox
24 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
25 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
26 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
27 A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia Completed NCT00001567 Phase 2 Roferon-A
28 Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab Completed NCT02157181 Phase 2 2CdA +/- Rituximab
29 BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia Completed NCT00074048 Phase 2 BL22
30 Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy Completed NCT00003757 Phase 2
31 Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation Completed NCT00005606 Phase 2
32 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
33 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
34 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
35 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
36 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
37 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
38 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
39 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
40 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
41 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
42 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
43 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
44 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
45 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
46 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
47 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
48 Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
49 Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
50 Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00003887 Phase 2

Search NIH Clinical Center for Hairy Cell Leukemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: leukemia, hairy cell

Genetic Tests for Hairy Cell Leukemia

Genetic tests related to Hairy Cell Leukemia:

id Genetic test Affiliating Genes
1 Hairy Cell Leukemia 29

Anatomical Context for Hairy Cell Leukemia

MalaCards organs/tissues related to Hairy Cell Leukemia:

39
Bone, Bone Marrow, B Cells, T Cells, Prostate, Liver, Kidney

Publications for Hairy Cell Leukemia

Articles related to Hairy Cell Leukemia:

(show top 50) (show all 716)
id Title Authors Year
1
Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. ( 28918710 )
2017
2
Time to cure hairy cell leukemia. ( 28840848 )
2017
3
Concomitant B Hairy Cell Leukemia and Mycosis Fungoides in an Elderly Man. ( 28512405 )
2017
4
Retrospective evaluation of hairy cell leukemia patients treated with 3 different first-line treatment modalities in the last two decades: a single center experience. ( 28747289 )
2017
5
Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence. ( 28302693 )
2017
6
Immunohistochemical Detection of Hairy Cell Leukemia in Paraffin Sections: The Role of Pax5 and CD103 Double Staining to Improve Specificity and Sensitivity. ( 28418282 )
2017
7
Purpuric exanthema in a patient with hairy cell leukemia treated with cladribine and allopurinol. ( 28391438 )
2017
8
Hairy cell leukemia: a case report of atypical presentation without splenomegaly. ( 28698853 )
2017
9
Bullous Pyoderma Gangrenosum Associated with Hairy Cell Leukemia and Its Complete Response to Cladribine Therapy. ( 28596664 )
2017
10
A rare breed: Wild-type braf and ighv expression in a 29 year old lady with classical hairy cell leukemia. ( 28275540 )
2017
11
An Unusual Giant Leg Ulcer as a Rare Presentation of Sweet's Syndrome in a Patient with Hairy Cell Leukemia Successfully Managed by Splenectomy. ( 28270371 )
2017
12
Genomics of Hairy Cell Leukemia. ( 28297625 )
2017
13
sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon-I+ therapy. ( 28214980 )
2017
14
Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population. ( 28778620 )
2017
15
Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis. ( 28485619 )
2017
16
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. ( 28801450 )
2017
17
Morphologic Confounders and CD19 Negativity in a Case of Hairy Cell Leukemia. ( 28512562 )
2017
18
Hairy Cell Leukemia in a Young Male: An Unusual Presentation. ( 28855936 )
2016
19
Neuroendocrine Differentiation of a Primary BRAF Mutant Colon Cancer in a Patient With aA History of Hairy Cell Leukemia. ( 27117521 )
2016
20
BRAF-V600E mutation in hairy cell leukemia: from bench to bedside. ( 27554081 )
2016
21
Hairy cell leukemia followed by polycythemia vera: report of the first case. ( 26941958 )
2016
22
Hairy cell leukemia-variant without typical morphology and with Near-tetraploid DNA Content. ( 27997757 )
2016
23
Synchronous or Metachronous Hairy Cell Leukemia and Chronic Lymphocytic Leukemia: A Case Series and Literature Review. ( 28119853 )
2016
24
CD10-Positive Hairy Cell Leukemia Involving Multiple Deep Lymph Nodes. ( 27013179 )
2016
25
Hairy Cell Leukemia and Bone Pain. ( 26679440 )
2016
26
BRAF inhibitor: targeted therapy in hairy cell leukemia. ( 27282942 )
2016
27
Long-term treatment of hairy cell leukemia with interferon-I+: still aA viable therapeutic option. ( 27429657 )
2016
28
A Unique Hairy Cell Leukemia Variant. ( 27462230 )
2016
29
Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant. ( 27241017 )
2016
30
Lymphocytosis, villi, and nucleoli: a variant of hairy cell leukemia. ( 28092880 )
2016
31
Audit of compliance with the British Committee for Standards in Haematology (BCSH) revised guidelines for the diagnosis and assessment of treatment response of hairy cell leukemia in University Hospital Galway. ( 27170271 )
2016
32
Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: a case report and review of the literature. ( 27002952 )
2016
33
CD5 positive hairy cell leukemia: A rare case report with brief review of literature. ( 27129891 )
2016
34
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia. ( 27790140 )
2016
35
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. ( 27903528 )
2016
36
CD27-positive hairy cell leukemia-Japanese variant. ( 26868143 )
2016
37
BRAF inhibition in hairy cell leukemia with low dose vemurafenib. ( 26941398 )
2016
38
Response of relapsed central nervous system hairy cell leukemia to vemurafenib. ( 27116997 )
2016
39
Refractory hairy cell leukemia-variant. ( 27727469 )
2016
40
Toxoplasmic Encephalitis with Untreated Hairy Cell Leukemia Variant. ( 27803415 )
2016
41
Ibrutinib for relapsed refractory hairy cell leukemia variant. ( 27733095 )
2016
42
Composite hairy cell leukemia and chronic lymphocytic leukemia. ( 27685932 )
2016
43
Unusual Soft Tissue Infiltrates With 18F-FDG Uptake in a Patient With Hairy Cell Leukemia. ( 25783506 )
2015
44
Hairy cell leukemia with ascites and coexistent histoplasmosis. ( 25673617 )
2015
45
Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia. ( 25511147 )
2015
46
Authentic caring occasions for patients in hairy cell leukemia clinical trials. ( 25840397 )
2015
47
Rituximab as frontline monotherapy in untreated hairy cell leukemia patients. ( 25672650 )
2015
48
The utility of BRAF V600E mutation-specific antibody VE1 for the diagnosis of hairy cell leukemia. ( 25511150 )
2015
49
BRAF V600E and MAP2K1 mutations in hairy cell leukemia and splenic marginal zone lymphoma cases. ( 25729732 )
2015
50
Chemoimmunotherapy for hairy cell leukemia. ( 26614901 )
2015

Variations for Hairy Cell Leukemia

Expression for Hairy Cell Leukemia

Search GEO for disease gene expression data for Hairy Cell Leukemia.

Pathways for Hairy Cell Leukemia

Pathways related to Hairy Cell Leukemia according to GeneCards Suite gene sharing:

(show all 29)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 ANXA1 BRAF CCND1 CD22 IFNA1 IFNA2
2
Show member pathways
13.71 BRAF IFNA1 IFNA2 IL2 IL2RA IL3
3
Show member pathways
13.36 BRAF IFNA1 IFNA2 IL2 IL2RA IL3
4
Show member pathways
13.17 IFNA1 IFNA2 IL2 IL2RA IL3 ITGAX
5
Show member pathways
12.92 ANXA1 BRAF CCND1 IFNA1 IFNA2 IL2
6
Show member pathways
12.9 BRAF IL2 IL2RA IL3 ITGAE ITGAX
7
Show member pathways
12.65 CCND1 IFNA1 IFNA2 IL2 IL2RA
8
Show member pathways
12.62 CCND1 IFNA1 IFNA2 IL2 IL2RA IL3
9 12.52 CCND1 IFNA1 IFNA2 IL2 IL2RA IL3
10 12.39 IFNA1 IL2 IL2RA IL3
11
Show member pathways
12.33 BRAF IFNA1 IFNA2 IL2 IL3
12
Show member pathways
12.05 BRAF CCND1 IL2RA ITGAE ITGAX
13 12.01 ANXA1 BRAF CCND1
14
Show member pathways
12.01 IFNA1 IFNA2 IL2 IL3
15
Show member pathways
12 IL2 IL2RA IL3
16 11.92 BRAF IFNA1 IFNA2
17
Show member pathways
11.89 BRAF IL2 IL2RA
18 11.86 ANXA1 CCND1 IL2
19 11.83 ANXA1 CCND1 ITGAX
20
Show member pathways
11.82 IL2 IL2RA IL3
21
Show member pathways
11.67 CCND1 IFNA1 IFNA2 IL2 IL2RA IL3
22 11.66 IL2 IL2RA ITGAE
23 11.66 CD22 CD5 IL2RA IL3
24
Show member pathways
11.62 IL2 IL2RA IL3
25 11.6 IFNA1 IFNA2 IL2 IL2RA IL3
26 11.57 BRAF IL2 IL3 ITGAE ITGAX
27
Show member pathways
11.51 BRAF IL2 IL2RA
28 11.5 IFNA2 IL2 ITGAE ITGAX
29 11.24 CD22 CD5 IFNA2 IL2 IL2RA IL3

GO Terms for Hairy Cell Leukemia

Cellular components related to Hairy Cell Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 ADA CD5 IL2RA ITGAE

Biological processes related to Hairy Cell Leukemia according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.89 ADA CD22 IL2 ITGAE ITGAX
2 cytokine-mediated signaling pathway GO:0019221 9.73 IFNA1 IFNA2 IL3
3 MAPK cascade GO:0000165 9.73 BRAF IL2 IL2RA IL3
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 IFNA2 IL2 IL3
5 response to X-ray GO:0010165 9.55 ANXA1 CCND1
6 T cell activation involved in immune response GO:0002286 9.54 IFNA1 IFNA2
7 positive regulation of T cell proliferation GO:0042102 9.54 ANXA1 IL2 IL2RA
8 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.52 IFNA1 IFNA2
9 natural killer cell activation involved in immune response GO:0002323 9.51 IFNA1 IFNA2
10 regulation of T cell differentiation GO:0045580 9.48 ADA BRAF
11 response to vitamin E GO:0033197 9.46 ADA CCND1
12 alpha-beta T cell differentiation GO:0046632 9.32 ANXA1 BRAF
13 negative regulation of lymphocyte proliferation GO:0050672 9.26 IL2 IL2RA
14 negative regulation of inflammatory response GO:0050728 9.26 ACP5 ADA IL2 IL2RA
15 regulation of T cell homeostatic proliferation GO:0046013 9.16 IL2 IL2RA
16 positive regulation of T cell differentiation GO:0045582 8.8 ADA IL2 IL2RA

Molecular functions related to Hairy Cell Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 type I interferon receptor binding GO:0005132 9.16 IFNA1 IFNA2
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.13 IL2 IL2RA IL3
3 cytokine activity GO:0005125 8.92 IFNA1 IFNA2 IL2 IL3

Sources for Hairy Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....